Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Response from the Manufacturer

Thrombotic Thrombocytopenia after Ad26.COV2.S Vaccination - Manufacturer's Response The manufacturer of the Ad26.COV2.S vaccine against Covid-19 comments on recent reports of thrombosis, including cerebral venous sinus thrombosis, associated with severe thrombocytopenia in several recipients of the vaccine.

Automated summary

The manufacturer responds to recent reports of thrombosis and severe thrombocytopenia in recipients of the Ad26.COV2.S vaccine.